Achiko AG Secures CHF 1.25 million Financing with Strategic Investors Buranto AG and Negma Group

- Buranto AG provided a CHF 250,000 loan facility and existing strategic investor Negma Group provided a CHF 1.0 million loan facility

- Derek Brandt, co-owner of Buranto AG, joins Achiko’s Advisory Board

- Funds to be used for production in Indonesia and initiate production in Taiwan to meet global demand for AptameX^TM which obtained a CE Mark earlier this month

Zurich, 25 May 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB:
ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces the completion of a CHF 1.25 million financing with strategic investors Buranto AG and Negma Group.

Buranto AG, a Swiss based company co-owned by Derek Brandt, has provided a loan facility of CHF 250,000 with the full amount drawn immediately. Derek Brandt will also join Achiko’s Advisory Board. Derek Brandt has more than 20 years general management and business development experience in MedTech, IVD, Pharma / Biotech and the Life Science Industry. Previous experience includes having served as Head of Clinical Development Group for Roche Diabetes and CEO of Sensile Medical.

Negma Group, one of the Company’s existing strategic shareholders, has provided a loan facility of CHF 1.0 million, with an immediate financing of CHF 500,000 and the balance to be drawn within the next 60 days.

“We’re excited and grateful to our shareholders, old and new”, said Steven Goh, CEO of Achiko AG. “Covid-19 is going to be with us a long time and the unique performance and customer experience characteristics of the company. With this financing we’re in a position to drive sales and do some good.”

The financing follows the Marketing and Sales agreement with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta (“PWNU”), the Jakarta District of Nahdlatul Ulama (“NU”), the largest Islamic organisation in the world and initiate global production in Taiwan to respond to interest in AptameX™ for expansion beyond Indonesia since obtaining a CE mark earlier this month.

ABOUT ACHIKO AG
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and an application for CE Mark approval in Europe will be submitted in 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX^TM and companion health apps via its digital mobile health technology division, Teman Sehat^TM. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta and Singapore.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.